Biotec Pharmacon develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The company is spearheading research on products that may prevent or treat diseases caused by failure, imbalance and over-reaction of the immune system.
The company has invested heavily in R&D and generated a portfolio of patents covering unique marine gene products for the molecular biology sector, and products with potentials within the pharmaceutical sector, such as beta-1,3/1,6-glucan formulations. The company has a strong foundation in basic research in both this and the recombinant technology sectors.
Basic research on the mode of action of the various proprietary beta-1,3/1,6-glucan products at a cellular/molecular level has been the foundation for scientific experiments with whole animals and a comprehensive series of commercial trials with various farm animals. Experience over a period of more than 20 years has confirmed that beta-1,3/1,6-glucan enhances overall disease resistance and improves health. Studies have shown that pure beta-1,3/1,6-glucan is a non-toxic modulator of various immune functions in the body, and affects many immunity related disorders.
Biotec Pharmacon has initiated a clinical development programme with drug candidates that enhance immunity and counteract the negative effects of immune related disorders. Product formulations that are effective when administered onto mucous surfaces, either alone or in combination with other medications or vaccines, have been given priority.
Beta-1,3/1,6-glucan interacts with cells that control innate immune mechanisms and orchestrates other immune reactions, especially the macrophages. The product therefore has many applications within human medicine, including general infection prophylaxis, immune therapy of cancer, and to counteract various sufferings that are related to imbalanced immune responses.
R&D-programs are also outsourced at cooperating academic and scientific institutions in Norway and abroad, in particular in the USA.
The intellectual property value of Biotec Pharmacon is being secured and developed through patents and trademarks, through control of the manufacturing technology and by a highly educated staff with a varied background and broad international experience.
Biotec Pharmacon ASA is the parent company of the group controlling two subsidiaries. All activities within the group related to administration, finance, and quality assurance are taken care of by the parent company, while the operations are separated in two entities; one for the marine enzymes, and one for the development and production of beta-glucans.
ArcticZymes AS is a supplier of enzymes with unique properties for molecular biology research and PCR based diagnostics. The company is currently supplying cold adapted and heat labile enzymes to leading international research reagents and diagnostics companies. ArcticZymes is 96% owned by Biotec Pharmacon.
Biotec BetaGlucans AS was established late 2010 to handle the beta-glucans operations previously organized within the parent company Biotec Pharmacon. As from 2011, Biotec BetaGlucans AS is handling all research and development, and manufacturing of beta-glucans within the group. Biotec BetaGlucans AS is wholly owned by Biotec Pharmacon.